Novartis to outsource 35% of API, 25% of biologics manufacturing, saves $120 M
Novartis will outsource 35% of API production and 25% of biologics fill-finish to CDMOs over two years, targeting $120 million in annual capex savings and freeing internal capacity. The move supports projected 8% CAGR in CDMO revenues through 2028 and could raise Novartis’ outsourcing spend by about 20%.
1. Outsourcing Details
Novartis will shift 35% of its small-molecule active pharmaceutical ingredient production and 25% of biologics fill-finish operations to external CDMOs over a two-year period, aiming to streamline its global manufacturing network and leverage specialized capacity for increased flexibility.
2. Financial Impact and Outlook
This strategy is expected to cut annual capital expenditures by about $120 million, reallocate internal facilities toward high-value pipeline projects and align with an industry trend of 8% annual growth in CDMO revenues through 2028, although total outsourcing expenses may rise by roughly 20%.